Background Thalidomide is an immunomodulatory agent with a spectrum of activity that is only partly characterized. Originally introduced as a nonbarbiturate hypnotic, it was used to treat …

Apr 23, 2021 · Lenalidomide is structurally similar to thalidomide, and as such is considered a teratogen with the potential to cause birth defects and fetal death. Lenalidomide is being …

Study aborted Inflammation 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 ALZT …

NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-1088 ABBV-552 ABBV-916 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine HCI ACI-24.060 …

Nov 25, 2015 · AD Target / Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within …

Queen Silvia of Sweden opened the 17th International Conference on Alzheimer’s and Parkinson’s Diseases, held March 28 to April 1 in Sweden's southwestern city of Gothenburg. …

Leqembi Phase 1, Phase 2, Phase 3 Levetiracetam Phase 2 NIC5-15 Phase 2 Octagam®10% Phase 2 Ponezumab Phase 2 Remternetug Phase 2/3, Phase 3 Simufilam Phase 2 …

Phase 2 NIC5-15 Phase 2 Neflamapimod Phase 2 Nelonicline Phase 2 ORM-12741 Phase 2 PF-05212377 Phase 2 Pioglitazone Phase 2, Phase 3 Piromelatine Phase 2 Relyvrio Phase 2 …

May 3, 2023 · When the scientists conjugated this sdAb to thalidomide to bind E3 ubiquitin ligase and trigger degradation of the complex, the treatment nearly eliminated aggregated α-synuclein.

Web page addresses and e-mail addresses turn into links automatically.